Compare Amgen, Inc. (AMGN) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Thomson Reuters Corp — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Thomson Reuters Corp trades at $89.65 (market cap $38.95B). The key difference: Amgen, Inc. is far larger — about 5× Thomson Reuters Corp's market cap, and Thomson Reuters Corp pays the higher dividend (2.92%). Which is the better fit depends on your goals.
| AMGN | TRI | |
|---|---|---|
Market Cap | $196.12B | $38.95B |
Sector | Health | Industrials |
52-Week High | $388.16 | $214.21 |
52-Week Low | $271.18 | $76.55 |
Enterprise Value | $241.41B | $40.91B |
Dividend Yield | 2.77% | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Thomson Reuters (TRI) trades at $89.65, up 0.92% today, with a bullish technical signal and strong support at $88. The company shows robust fundamentals with a 19.93% net income margin and consistent earnings beats, though Q4 2025 missed expectations. Recent AI partnerships and a special dividend highlight strategic moves, while cash flow turned negative in 2025 due to investing activities.
Outlook is positive with a consensus price target of $129.96, implying 45% upside, supported by 51.85% analyst buy ratings. Risks include AI implementation challenges and revenue volatility, but the stock's valuation at P/E 25.8 appears reasonable given growth prospects in legal and compliance sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
